UK’s NICE wants more ef­fec­tive­ness da­ta on Lil­ly’s tirzepatide

Last year
Pharma

Off-the-shelf and on the de­cline: Adicet Bio’s shares halved af­ter PhI look at cell ther­a­py

Last year
R&D
Cell/Gene Tx

What got on­col­o­gy ex­perts talk­ing and tweet­ing at AS­CO? Har­ris Poll sur­vey finds it was more than just da­ta

Last year
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er re­ups sick­le cell cam­paign with NFL play­er; Alk­er­mes aims for bipo­lar pa­tients with TV ad

Last year
Pharma
Marketing

Life sci­ence VC Ver­tex Ven­tures HC rais­es $200M in new fund

Last year
Financing

Emer­gent BioSo­lu­tions CEO Robert Kramer an­nounces re­tire­ment

Last year
People
Manufacturing

Af­ter cut­ting back on Vuity last fall, Ab­b­Vie culls a sec­ond-gen pres­by­opia eye drop

Last year
R&D
Pharma

Nkar­ta breaks si­lence on CAR-NK ther­a­py for AML af­ter a year, shares tum­ble

Last year
R&D
Cell/Gene Tx

Aldeyra says its can­di­date won in chron­ic cough PhII, set­ting stage for bout with Mer­ck, GSK

Last year
R&D

Xen­tria and Meitheal ink li­cens­ing deal for rare lung dis­ease treat­ment in North Amer­i­ca

Last year
Deals
R&D

FDA ap­proves first of two UCB myas­the­nia gravis drugs, fol­low­ing Alex­ion and ar­genx’s lead

Last year
R&D
FDA+

Lu­minopia scores $16M for vir­tu­al re­al­i­ty-based lazy eye treat­ment

Last year
Financing

Top drug from Sanofi’s $1.5B Kymab buy­out aces PhI­Ib in eczema

Last year
R&D

Moon­Lake's mid-stage IL-17 da­ta sent shares sky­rock­et­ing. Now it plans to sell $250M in stock

Last year
Financing

Il­lu­mi­na lays off work­ers and cuts of­fice foot­print as part of cost-re­duc­tion mea­sures

Last year
People

Lil­ly’s pipeline drug re­ta­tru­tide sets new thresh­old for weight loss at med­ical meet­ing re­veal

Last year
R&D

Ser­no­va says five di­a­betes pa­tients have now been tak­en off in­sulin af­ter 'cell pouch' ther­a­py

Last year
R&D

Rep. Pal­lone push­es House Re­pub­li­cans to ad­dress drug short­ages in PAH­PA reau­tho­riza­tion

Last year
Pharma
Manufacturing

J&J touts PhII da­ta in rare blood dis­or­der as it plots a piv­otal study

Last year
R&D
Pharma

UK's Na­tion­al Can­cer Re­search In­sti­tute to shut down, cit­ing 'risk of op­er­a­tional fail­ure'

Last year
Pharma

FDA re­view­ers on Ipsen's po­ten­tial ul­tra-rare dis­ease drug: Post-hoc analy­sis may be enough

Last year
FDA+

Pfiz­er’s alope­cia tablet ap­proved by FDA in adults and teens, win­ning broad­er mar­ket than Lil­ly's Olu­mi­ant

Last year
Pharma
FDA+

GSK set­tles key Zan­tac case ahead of tri­al

Last year
Pharma
Law

Sutro inks $390M roy­al­ty fi­nanc­ing deal with Black­stone; Clin­i­cal hold on Phar­varis' HAE drug lift­ed

Last year
News Briefing
First page Previous page 320321322323324325326 Next page Last page
A service from the Financial Times